

STANDARDS
STANDARDS
STANDARDS
STANDARDS
STANDARDS
STANDARDS
STANDARDS

International standards for the treatment of drug use disorders

REVISED EDITION
INCORPORATING RESULTS
OF FIELD-TESTING



World Health
Organization



UNODC

United Nations Office on Drugs and Crime

International standards for the treatment of drug use disorders

REVISED EDITION
INCORPORATING RESULTS
OF FIELD-TESTING



International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing

ISBN 978-92-4-000219-7 (electronic version)

ISBN 978-92-4-000220-3 (print version)

© World Health Organization and United Nations Office on Drugs and Crime, 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO or UNODC endorses any specific organization, products or services. The unauthorized use of the WHO or UNODC names or logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO) or the United Nations Office on Drugs and Crime (UNODC). Neither WHO nor UNODC are responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

Suggested citation. International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing. Geneva: World Health Organization and United Nations Office on Drugs and Crime; 2020. License: CC BY-NC-SA 3.0 IGO.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO or UNODC concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific organizations, companies or of certain products or programmes does not imply that they are endorsed or recommended by WHO or UNODC in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO and UNODC to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO or UNODC be liable for damages arising from its use.

Design and layout by L'IV Com Sàrl

Printed in Switzerland

Contents

Acknowledgements	v
------------------	---

Chapter 1. Introduction	1
1.1 Objectives and target audience of the International Standards	1
1.2 Development of <i>the Standards</i>	2
1.3 Drug use, drug use disorders and treatment needs	3

Chapter 2. Key principles and standards for the treatment of drug use disorders	7
Principle 1. Treatment should be available, accessible, attractive, and appropriate	8
Principle 2. Ensuring ethical standards of care in treatment services	9
Principle 3. Promoting treatment for drug use disorders through effective coordination between the criminal justice system and health and social services	10
Principle 4. Treatment should be based on scientific evidence and respond to the specific needs of individuals with drug use disorders	11
Principle 5. Responding to the special treatment and care needs of population groups	12
Principle 6. Ensuring good clinical governance of treatment services and programmes for drug use disorders	13
Principle 7. Treatment services, policies and procedures should support an integrated treatment approach, and linkages to complementary services require constant monitoring and evaluation	14

Chapter 3. Treatment systems for drug use disorders	15
3.1 System level of service provision	15
3.2 Treatment system organization	16
3.2.1 Suggested interventions at different system levels	18
3.3 Planning and funding of treatment systems	19
3.4 Models of service organization	19
3.4.1 A one-stop-shop approach	19
3.4.2 Community-based network approach	20
3.4.3 Sustained recovery management	23
3.5 Effective treatment systems: conclusions	24

Chapter 4. Treatment settings, modalities and interventions	26
4.1 Treatment settings	28
4.1.1 Community-based outreach	28
4.1.2 Settings not specialized for the treatment of people with substance use disorders	33
4.1.3 Specialized outpatient treatment	35
4.1.4 Specialized short-term inpatient treatment	39
4.1.5 Specialized long-term or residential treatment	44
4.2 Treatment modalities and interventions	54
4.2.1 Screening, brief interventions and referral to treatment	54
4.2.2 Evidence-based psychosocial interventions	56
4.2.3 Evidence-based pharmacological interventions	59
4.2.4 Overdose identification and management	65
4.2.5 Treatment of co-occurring psychiatric and physical health conditions	67
4.2.6 Recovery management	71
Chapter 5. Populations with special treatment and care needs	77
5.1 Pregnant women with drug use disorders	77
5.1.1 Description	77
5.1.2 Models and components	78
5.1.3 Management of newborn infants passively exposed to opioids <i>in utero</i>	83
5.1.4 Staff training and documentation	84
5.2 Children and adolescents with substance use disorders	85
5.2.1 Description	85
5.2.2 Models and components	86
5.3 Drug use disorders among people in contact with the criminal justice system	89
5.3.1 Description	89
5.3.2 Models and components	90
5.3.3 Treatment as an alternative to conviction or punishment	93
5.3.4 Treatment in prison settings	94
References	96

Acknowledgements

The United Nations Office on Drugs and Crime and the World Health Organization would like to acknowledge the individuals and organizations listed below for their invaluable contribution to the development of *the Standards*.

The international experts, who provided the relevant scientific evidence and technical advice and developed the draft of the Standards for field-testing, includes: Dr David Basangwa, Uganda; Dr Adam Bisaga, the United States of America (USA); Dr Sandra Brown, USA; Mr Thom Browne, USA; Dr Kathleen Carroll, USA; Dr Michael Clark, USA; Dr Loretta Finnegan, USA; Dr Gabriele Fischer, Austria; Dr Hendree Jones, USA; Dr Martien Kooyman, the Netherlands; Dr Evgeny Krupitsky, the Russian Federation; Dr Otto Lesch, Austria; Dr Icro Maremmani, Italy; Dr Douglas Marlowe, USA; Dr Andrew Thomas McLellan, USA; Dr Edward Nunes, USA; Dr Isidore Obot, Nigeria; Dr John Strang, the United Kingdom; Dr Emilis Subata, Lithuania; Dr Marta Torrens, Spain; Dr Roberto Tykanori Kinoshita, Brazil; Dr Riza Sarasvita, Indonesia; Dr Willem Van Den Brink and Dr Lucas George Wiessing, the Netherlands; The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), in particular Dr Marica Ferri; the National Institute of Drug Abuse (NIDA), USA, in particular Dr Steve Gust; the Inter-American Drug Abuse Control Commission (CICAD), in particular Ms Alexandra Hill; the Substance Abuse and Mental Health Services Administration (SAMHSA), USA, in particular Mr Humberto Carvalho; the Colombo Plan, in particular Ms Veronica Felipe, Mr Bian How Tay and Ms Winona Pandan.

Special thanks are due to Dr Gilberto Gerra, UNODC, and Dr Vladimir Poznyak, WHO, for coordinating this collaborative effort of UNODC and WHO as part of the UNODC-WHO Programme on Drug Dependence Treatment and Care.

Special thanks are also due to WHO staff and consultants, in particular Dr Shekhar Saxena and Dr Nicolas Clark for their significant contribution to the development of the draft of the Standards for field-testing; Dr Dzmitry Krupchanka for his pivotal role in the planning and implementation of the field-testing of the Standards, analysis of field-test results and subsequent revision of the document; Dr Andrew Ball, Dr Gilles Forte and Mrs Annette Verster for their contributions to the finalization of the document, and Dr Dévora Kestel for overall guidance and support at the final stages of the document's development; Dr Luis Alfonso (Pan American Health Organization (PAHO)) and Dr Khalid Saeed (WHO Regional Office for the Eastern Mediterranean) for their support of the field-testing in the WHO Region of the Americas and the WHO Region for the Eastern Mediterranean; and the following WHO consultants and interns for their contribution to data analysis (in alphabetical order): Ms Elise Gehring, Ms Aikaterini Georgopoulou, Ms Eloise Harrison, Ms Ruchika Jain, Mr Cesar Leos-Toro and Dr Nirvana Morgan.

The following UNODC staff made significant contribution to the drafting, development and finalization of the Standards (in alphabetical order): Ms Anja Busse, Ms Giovanna Campello, Dr Igor Koutsenok, Ms Elizabeth Mattfeld, Dr Elizabeth Saenz, and Dr Wataru Kashino. UNODC consultants, Ms Christina Gamboa, Mr Jan-Christopher Gumm and Ms Olga Parakkal supported the development of the first draft of the Standards and the field-testing process. Ms Annette Dale-Perera made an invaluable contribution to the review and revision of *the Standards*.

The following individuals and organizations played key roles in the field-testing of the draft version of the Standards (in alphabetical order): Dr Atul Ambekar (National Drug Dependence Treatment Centre, India); Dr Sawitri Assanangkornchai and Dr Uriwan Pattanasttayawong (Prince of Songkla University, Thailand); Dr Eva Suryani (Atma Jaya Catholic University of Indonesia, Indonesia); Dr José Manoel Bertolote (Botucatu Medical School, Brazil); Dr Adrian Dunlop (Drug & Alcohol Clinical Services, NSW, Australia); Dr Carlos Ibáñez (Department of Psychiatry and Mental Health, Universidad de Chile, Santiago de Chile, Chile); Dr María Elena Medina-Mora (National Institute of Psychiatry, Mexico); Dr Afarin Rahimi-Movaghar (Iranian National Center for Addiction Studies, Islamic Republic of Iran); Dr Min Zhao and Dr Na Zhong (Shanghai Mental Health Center, China).

The following individuals provided additional feedback on the draft Standards: Dr Oleg Aizberg and Dr Alexey Alexandrov (Belarusian Academy for Postgraduate Education, Belarus); Dr Kathleen T. Brady and Dr Khan Riaz Ahmad (the Board of the International Society of Addiction Medicine); Dr Geert Dom (European Federation of Addiction Societies); Dr Yasser Khazaal (Geneva University Hospital, Switzerland); Dr Michael P. Schaub (Swiss Research Institute for Public Health and Addiction, Switzerland); Dr Tuukka Tammi (National Institute for Health and Welfare, Finland).

Special thanks are also due to the hundreds of clinicians, service managers, public health specialists, researchers, service users, representatives of academia and civil society groups who were involved in field-testing in the above-listed sites or provided feedback on the earlier versions of the document.

The following administrative staff of UNODC and WHO provided organizational support with dedication throughout the development of the International Standards: Ms Caecilia Handayani-Hassmann, Ms Emilie Finkelstein, Ms Nataliya Graninger, Ms Divina Maramba and Mr Bojan Misosavljevic.

UNODC staff in the field offices and WHO staff in the country offices provided substantive support for the field-testing of the Standards and overall project implementation.

Ms Dorothy Lusweti (Switzerland) provided copy-editing for this document.

Last, but not least, WHO and UNODC gratefully acknowledge the financial support provided by the International Narcotics and Law Enforcement Affairs (INL) Program of the United States Department of State for the development, field-testing and finalization of *the Standards*.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24727

